Sign in
4

Changes in Ownership

Axogen, Inc. Filed Acc 0000805928-24-000047

Chief R&D Officer sold 6,881 shares at $7.68 ($52,846)

  • Chief R&D Officer acquired 27,906 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Scopelianos Angelo · Chief R&D Officer

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2024-03-16 Exercise or conversion : show line 1 in the form +21,281 58,250 D
2024-03-21 Sale : show line 2 in the form −5,251 $7.68 $40,328 52,999 D
2024-03-16 Exercise or conversion : show line 3 in the form +4,125 57,124 D
2024-03-21 Sale : show line 4 in the form −1,020 $7.68 $7,834 56,104 D
2024-03-21 Exercise or conversion : show line 5 in the form +2,500 58,604 D
2024-03-21 Sale : show line 6 in the form −610 $7.68 $4,685 57,994 D
Open-market sales · 6,881 sh · avg $7.68 · $52,846

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2024-03-16 Exercise or conversion : show line 7 in the form Restricted Stock Units −21,281 21,282 D
2024-03-16 Exercise or conversion : show line 8 in the form Restricted Stock Units −4,125 4,125 D
2024-03-16 Exercise or conversion : show line 9 in the form Restricted Stock Units −2,500 0 D
Loading xslF345X05/wk-form4_1711417017.xml…